<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene T95I;Y144delinsTSN;R346K;E484K;N501Y;D614G;P681H literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.T95I;Y144delinsTSN;R346K;E484K;N501Y;D614G;P681H</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus.<br/>Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.  (<a href="https://doi.org/10.1056/NEJMc2104036" class="lit_link">Luftig et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Sera from individuals who have been infected with Delta does not have strong neutralising activity against B.1.621 (<a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf" class="lit_link">PHE UK (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_efficacy">Vaccine efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 69 test-positive were Mu.<br/>Two dose vaccine efficacy against Mu was 90.4% (73.9-96.5%), one dose VE was 45.8% (0.0-88.9%). (<a href="https://doi.org/10.1101/2021.09.29.21264199" class="lit_link">Bruxvoort et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Sera from vaccinees [ChAdOx1 and BNT162b2 primarily used in UK] shows decreased ability to neutralize B.1.621 compared to first wave virus and Alpha, with a magnitude of change similar to Beta.<br/> (<a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf" class="lit_link">PHE UK (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against B.1.621.<br/> (<a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf" class="lit_link">PHE UK (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
